Healthdirect Free Australian health advice you can count on.

Medical problem? Call 1800 022 222. If you need urgent medical help, call triple zero immediately

healthdirect Australia is a free service where you can talk to a nurse or doctor who can help you know what to do.

beginning of content

Brand name: Mabthera

Mabthera is a medicine containing the active ingredient(s) rituximab. On this page you will find out more about Mabthera, including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)

You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.

Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.

Active ingredient in this medicine: rituximab

Pack size information

Please select the pack size from the options directly below to view information on the medicine.

Information for medicine and pack size:
Mabthera 100 mg/10 mL concentrated injection, 2 x 10 mL vials

Consumer Medicine Information leaflet:

This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.

Read leaflet

What this medicine is for

Non-Hodgkin's Lymphoma: MABTHERA is indicated for treatment of patients with: CD20 positive, previously untreated, Stage III/IV follicular, B-cell non-Hodgkin's lymphoma. CD20 positive, relapsed or refractory low grade or follicular, B-cell non-Hodgkin's lymphoma, CD20 positive, diffuse large B-cell non-Hodgkin's lymphoma, in combination with chemotherapy. Chronic Lymphocytic Leukaemia: MABTHERA is indicated for the treatment of patients with CD20 positive chronic lymphocytic leukaemia (CLL) in combination with chemotherapy. Rheumatoid Arthritis: MABTHERA (rituximab) in combination with methotrexate is indicated for the treatment of adult patients with severe, active rheumatoid arthritis who have had an inadequate response or intolerance to at least one tumour necrosis factor (TNF) inhibitor therapy. MABTHERA has been shown to reduce the rate of progression of joint damage as measured by x-ray when given in combination with methotrexate. Granulomatosis with polyangiitis (Wegener's ) (GPA) and Microscopic polyangiitis (MPA). MABTHERA in combination with glucocorticoids is indicated for the induction of remission in patients with severely active Granulomatosis with polyangiitis (GPA, also known as Wegener's granulomatosis) and Microscopic polyangiitis (MPA). The efficacy and safety of retreatment with MABTHERA have not been established.

Table of characteristics
Table of characteristics
Active ingredient
Visual appearance Clear to opalescent, colourless to pale yellow liquid.
Dosage Form Injection, concentrated
Route of administration Intravenous
Medicine schedule
2 vials: Prescription Only Medicine, or Prescription Animal Remedy

There is one type of pack available.

Pack type 1
Pack type 1
Type Vial
Storage temperature Store at 2 to 8 degrees Celsius
Storage conditions Refrigerate,Protect from Light,Do not Freeze
Life time 30 Months
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on 1 November 2017

The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.

Go to PBS site

Is this medication banned in sport?

Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.

Go to ASADA site

The information displayed on this page is authored by Healthdirect Australia, or obtained from trusted sources.

Need more information?

These trusted information partners have more on this topic.

Found 6 results

Mabthera Concentrate for infusion - myDr.com.au

Mabthera Concentrate for infusion - Consumer Medicines Information leaflets of prescription and over-the-counter medicines

Read more on myDr – Consumer Medicine Information website

Mabthera SC Solution for injection - myDr.com.au

Mabthera SC Solution for injection - Consumer Medicines Information leaflets of prescription and over-the-counter medicines

Read more on myDr – Consumer Medicine Information website

MabThera (rituximab (rch)) information | myVMC

MabThera (rituximab (rch)) is used to treat rheumatoid arthritis, granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis.

Read more on myVMC – Virtual Medical Centre website

Entyvio Powder for infusion - myDr.com.au

Entyvio Powder for infusion - Consumer Medicines Information leaflets of prescription and over-the-counter medicines

Read more on myDr – Consumer Medicine Information website

Simponi prefilled syringe Solution for injection - myDr.com.au

Simponi prefilled syringe Solution for injection - Consumer Medicines Information leaflets of prescription and over-the-counter medicines

Read more on myDr – Consumer Medicine Information website

Xeljanz Tablets - myDr.com.au

Xeljanz Tablets - Consumer Medicines Information leaflets of prescription and over-the-counter medicines

Read more on myDr – Consumer Medicine Information website

Check your symptoms Find a health service

Healthdirect 24hr 7 days a week hotline

24 hour health advice and information you can count on

1800 022 222

Government Accredited with over 140 information partners

We are a government-funded service, providing quality, approved health information

Australian Government, health department logo ACT Government logo New South Wales government, health department logo Northen Territory Government logo Government of South Australia, health department logo Tasmanian government logo Government of Western Australia, health department logo
Feedback